INNOVATING NOVEL PEPTIDE THERAPEUTICS
With our groundbreaking peptide technology platform, Protagonist is bringing forward novel peptide therapeutics in late-stage clinical development with the potential to radically improve the treatment of both rare and prevalent diseases. We address a diverse set of biological targets and pathways for which classical small molecule or biologics approaches are less effective or less preferable to physicians and patients.
Our pipeline includes rusfertide, a peptide mimetic of the natural hormone hepcidin, which is currently being investigated in the phase 3 clinical study VERIFY for polycythemia vera, a rare disease characterized by excessive red blood cell production. We are also advancing PN-235, an oral peptide IL-23 receptor antagonist partnered with Janssen Pharmaceutical Companies of Johnson & Johnson.
Visionary Leadership with a Record of Success
Led by Dinesh Patel, President and CEO, the Protagonist executive leadership team leverages decades of experience and expertise in drug discovery, clinical development, and commercialization to serve patients most in need.
Supportive and Effective Board of Directors
The board of directors serves as a valuable and effective leadership arm. Working closely with the Protagonist executive leadership team, the board offers insight and support to the Protagonist scientific and business strategy.
Solid Investment in Remarkable, Life-Changing Drug Therapies
We are a publicly traded biopharmaceutical company. We make amazing scientific discoveries and then turn those scientific breakthroughs into life-changing medicine for people who need them most.